文献速递肝病

经活检证实的非酒精性脂肪性肝病患者中糖尿病患者的纤维化进展率:一项多中心研究

Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study.
PubMed 文献 · Gastroenterology · 2023-04-29

该多中心队列纳入447例有配对肝活检的非酒精性脂肪性肝病成人,比较合并与不合并2型糖尿病者的纤维化进展。合并2型糖尿病者4年、8年、12年纤维化进展累积发生率更高,校正混杂后2型糖尿病仍为独立预测因素,纤维化逆转两组相似。

要点

  • 合并2型糖尿病者纤维化进展累积发生率4年24% vs 20%,8年60% vs 50%,12年93% vs 76%。
  • 校正多因素后2型糖尿病仍为纤维化进展的独立预测因素,校正风险比1.69。
  • 纤维化逆转≥1期的累积发生率在合并与不合并2型糖尿病者间相似。

核心结论

  • 在经活检证实且有配对肝活检的非酒精性脂肪性肝病成人中,合并2型糖尿病者纤维化进展快于不合并2型糖尿病者。

研究设计与样本

  • 多中心队列研究,纳入447例成人非酒精性脂肪性肝病参与者(64%为女性),均有间隔超过1年的配对肝活检。
  • 肝组织学由对临床数据设盲的中心病理委员会系统评估。
  • 主要结局为合并与不合并2型糖尿病者纤维化进展≥1期的累积发生率。

主要发现

  • 参与者平均(标准差)年龄50.9(11.5)岁,平均(标准差)体重指数34.7(6.3)。
  • 两次活检中位时间3.3年(四分位距1.8-6.1年)。
  • 合并2型糖尿病者纤维化进展累积发生率4年24% vs 20%,8年60% vs 50%,12年93% vs 76%(P = .005)。
  • 多因素Cox比例风险模型校正多个混杂因素后,2型糖尿病仍为纤维化进展的独立预测因素(校正风险比1.69;95% CI 1.17-2.43;P = .005)。
  • 纤维化逆转≥1期的累积发生率在合并与不合并2型糖尿病者间相似(P = .24)。

关键数值与推荐

  • 合并2型糖尿病者纤维化进展累积发生率4年24% vs 不合并者20%(P = .005)。
  • 合并2型糖尿病者纤维化进展累积发生率8年60% vs 不合并者50%(P = .005)。
  • 合并2型糖尿病者纤维化进展累积发生率12年93% vs 不合并者76%(P = .005)。
  • 校正风险比1.69(95% CI 1.17-2.43;P = .005)。

临床怎么用

  • 这些数据对临床实践和试验设计具有重要意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There are limited data regarding fibrosis progression in biopsy-proven nonalcoholic fatty liver disease (NAFLD) in people with type 2 diabetes mellitus (T2DM) compared with people without T2DM. We assessed the time to fibrosis progression in people with T2DM compared with people without T2DM in a large, multicenter, study of people with NAFLD who had paired liver biopsies. METHODS: This study included 447 adult participants (64% were female) with NAFLD who had paired liver biopsies more than 1 year apart. Liver histology was systematically assessed by a central pathology committee blinded to clinical data. The primary outcome was the cumulative incidence of a ≥1-stage increase in fibrosis in participants with T2DM compared with participants without T2DM. RESULTS: The mean (SD) age and body mass index (calculated as weight in kilograms divided by the square of the height in meters) were 50.9 (11.5) years and 34.7 (6.3), respectively. The median time between biopsies was 3.3 years (interquartile range, 1.8-6.1 years). Participants with T2DM had a significantly higher cumulative incidence of fibrosis progression at 4 years (24% vs 20%), 8 years (60% vs 50%), and 12 years (93% vs 76%) (P = .005). Using a multivariable Cox proportional hazards model adjusted for multiple confounders, T2DM remained an independent predictor of fibrosis progression (adjusted hazard ratio, 1.69; 95% CI, 1.17-2.43; P = .005). The cumulative incidence of fibrosis regression by ≥1 stage was similar in participants with T2DM compared with participants without T2DM (P = .24). CONCLUSIONS: In this large, multicenter cohort study of well-characterized participants with NAFLD and paired liver biopsies, we found that fibrosis progressed faster in participants with T2DM compared with participants without T2DM. These data have important implications for clinical practice and trial design.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Huang DQ, Wilson LA, Behling C, et al. Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study. Gastroenterology. 2023. PMID: 37127100. doi:10.1053/j.gastro.2023.04.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。